Skip to main content
. 2020 Nov 20;11:580622. doi: 10.3389/fphar.2020.580622

TABLE 3.

Major bleeding across studies.

Ibrutinib Control
B-cell malignancies (%) 71/2,357 (3.0%) 30/1931 (1.6%)
CLL (%) 44/1727 (2.5%) 14/1,299 (1.1%)
First-line (%) 39/1,577 (2.5%) 11/1,182 (0.9%)
Relapsed/refractory (%) 29/725 (4.0%) 16/674 (2.4%)

The percentage (%) is calculated from the events/total number of patients. CLL, chronic lymphocytic leukemia.